GLP1R and diabetes mellitus: Recent evidence showed that sodium glucose linked transporter 2 (SGLT-2) inhibitors (4) and glucagon-like peptide 1 (GLP-1) receptor agonists (5) improved cardiovascular prognosis of patients with diabetes and high cardiovascular risk.